tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

Cytokinetics upgraded to Buy at Goldman on odds of ACACIA succeeding
The FlyCytokinetics upgraded to Buy at Goldman on odds of ACACIA succeeding
19h ago
BMY
CYTK
Bristol Myers price target raised to $57 from $51 at Goldman Sachs
PremiumThe Fly
Bristol Myers price target raised to $57 from $51 at Goldman Sachs
4d ago
BMY
Bristol Myers upgraded to Buy at BofA on pipeline strength
PremiumThe Fly
Bristol Myers upgraded to Buy at BofA on pipeline strength
4d ago
BMY
Bristol Myers upgraded to Buy from Neutral at BofA
PremiumThe Fly
Bristol Myers upgraded to Buy from Neutral at BofA
4d ago
BMY
Midday Fly By: Broadcom slides, pot stocks jump
PremiumThe Fly
Midday Fly By: Broadcom slides, pot stocks jump
7d ago
C
NX
Roblox downgraded, Lululemon upgraded: Wall Street’s top analyst calls
PremiumThe FlyRoblox downgraded, Lululemon upgraded: Wall Street’s top analyst calls
7d ago
C
BA
Bristol Myers price target raised to $37 from $36 at Morgan Stanley
Premium
The Fly
Bristol Myers price target raised to $37 from $36 at Morgan Stanley
7d ago
BMY
Bristol Myers upgraded to Buy at Guggenheim ahead of 2026
Premium
The Fly
Bristol Myers upgraded to Buy at Guggenheim ahead of 2026
7d ago
BMY
Bristol Myers upgraded to Buy from Neutral at Guggenheim
PremiumThe Fly
Bristol Myers upgraded to Buy from Neutral at Guggenheim
7d ago
BMY
Cautious Hold Rating on Bristol-Myers Squibb Amid Competitive Pressures in Hematology
PremiumRatings
Cautious Hold Rating on Bristol-Myers Squibb Amid Competitive Pressures in Hematology
7d ago
BMY
Bristol Myers says FDA grants priority review to sBLA for Opdivo
PremiumThe Fly
Bristol Myers says FDA grants priority review to sBLA for Opdivo
8d ago
BMY
Bristol Myers raises quarterly dividend 1.6% to 63c per share
PremiumThe Fly
Bristol Myers raises quarterly dividend 1.6% to 63c per share
8d ago
BMY
Bristol Myers price target raised to $53 from $50 at HSBC
PremiumThe FlyBristol Myers price target raised to $53 from $50 at HSBC
9d ago
BMY
Trump Weekly: President approves U.S. manufacturing of ‘tiny cars’
Premium
The Fly
Trump Weekly: President approves U.S. manufacturing of ‘tiny cars’
13d ago
F
GM
Bristol Myers’ Breyanzi approved by FDA as CAR-T therapy for MZL
Premium
The Fly
Bristol Myers’ Breyanzi approved by FDA as CAR-T therapy for MZL
14d ago
BMY
FDA shift in drug study requirements sends trial runners lower
PremiumThe Fly
FDA shift in drug study requirements sends trial runners lower
15d ago
AZN
BMY
FDA to reduce number of trials required for drug approvals, STAT reports
PremiumThe Fly
FDA to reduce number of trials required for drug approvals, STAT reports
15d ago
AZN
BMY
FDA to reduce number of trials required for drug approvals, STAT reports
PremiumThe Fly
FDA to reduce number of trials required for drug approvals, STAT reports
15d ago
AZN
BMY
Bristol Myers price target raised to $53 from $45 at Scotiabank
PremiumThe Fly
Bristol Myers price target raised to $53 from $45 at Scotiabank
15d ago
BMY
Sell Rating on Bristol-Myers Squibb Due to Cobenfy Trial Challenges and Uncertain Sales Forecast
PremiumRatingsSell Rating on Bristol-Myers Squibb Due to Cobenfy Trial Challenges and Uncertain Sales Forecast
15d ago
BMY
Leerink views ADEPT-2 update as positive news, keeps Outperform on Bristol Myers
Premium
The Fly
Leerink views ADEPT-2 update as positive news, keeps Outperform on Bristol Myers
15d ago
BMY
ADEPT-2 news ‘at face is a win’ for MapLight Therapeutics, says Stifel
Premium
The Fly
ADEPT-2 news ‘at face is a win’ for MapLight Therapeutics, says Stifel
16d ago
BMY
MPLT

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >